Bocunebart for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Nov 2021: Trial started, NCT05133323
  2. 24 Nov 2021: Trial registered, NCT05133323

The trials

NCT05133323: A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

State
Completed
Phase
Phase 2
People
237 taking part
Started
11 Nov 2021
Primary completion
19 Jan 2023
Arms
Lu AG09222 High Dose, Lu AG09222 Low Dose
Results
Posted on the registry
  1. 11 Nov 2021: Trial started
  2. 24 Nov 2021: Trial registered
  3. 16 Mar 2023: Trial completed
  4. 8 Feb 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.